Literature DB >> 15791438

Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial.

Nanda C Krak1, R Boellaard, Otto S Hoekstra, Jos W R Twisk, Corneline J Hoekstra, Adriaan A Lammertsma.   

Abstract

PURPOSE: Quantitative measurement of tracer uptake in a tumour can be influenced by a number of factors, including the method of defining regions of interest (ROIs) and the reconstruction parameters used. The main purpose of this study was to determine the effects of different ROI methods on quantitative outcome, using two reconstruction methods and the standard uptake value (SUV) as a simple quantitative measure of FDG uptake.
METHODS: Four commonly used methods of ROI definition (manual placement, fixed dimensions, threshold based and maximum pixel value) were used to calculate SUV (SUV([MAN]), SUV15 mm, SUV50, SUV75 and SUVmax, respectively) and to generate "metabolic" tumour volumes. Test-retest reproducibility of SUVs and of "metabolic" tumour volumes and the applicability of ROI methods during chemotherapy were assessed. In addition, SUVs calculated on ordered subsets expectation maximisation (OSEM) and filtered back-projection (FBP) images were compared.
RESULTS: ROI definition had a direct effect on quantitative outcome. On average, SUV[MAN), SUV15 mm, SUV50 and SUV75, were respectively 48%, 27%, 34% and 15% lower than SUVmax when calculated on OSEM images. No statistically significant differences were found between SUVs calculated on OSEM and FBP reconstructed images. Highest reproducibility was found for SUV15 mm and SUV[MAN] (ICC 0.95 and 0.94, respectively) and for "metabolic" volumes measured with the manual and 50% threshold ROIs (ICC 0.99 for both). Manual, 75% threshold and maximum pixel ROIs could be used throughout therapy, regardless of changes in tumour uptake or geometry. SUVs showed the same trend in relative change in FDG uptake after chemotherapy, irrespective of the ROI method used.
CONCLUSION: The method of ROI definition has a direct influence on quantitative outcome. In terms of simplicity, user-independence, reproducibility and general applicability the threshold-based and fixed dimension methods are the best ROI methods. Threshold methods are in addition relatively independent of changes in size and geometry, however, and may therefore be more suitable for response monitoring purposes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15791438     DOI: 10.1007/s00259-004-1566-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  34 in total

1.  Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling.

Authors:  R Boellaard; A van Lingen; A A Lammertsma
Journal:  J Nucl Med       Date:  2001-05       Impact factor: 10.057

2.  Breast imaging with fluorine-18-FDG PET: quantitative image analysis.

Authors:  N Avril; S Bense; S I Ziegler; J Dose; W Weber; C Laubenbacher; W Römer; F Jänicke; M Schwaiger
Journal:  J Nucl Med       Date:  1997-08       Impact factor: 10.057

3.  Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.

Authors:  A C Kole; O E Nieweg; J Pruim; A M Paans; J T Plukker; H J Hoekstra; H Schraffordt Koops; W Vaalburg
Journal:  J Nucl Med       Date:  1997-05       Impact factor: 10.057

4.  Reproducibility of metabolic measurements in malignant tumors using FDG PET.

Authors:  W A Weber; S I Ziegler; R Thödtmann; A R Hanauske; M Schwaiger
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

5.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

6.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.

Authors:  I C Smith; A E Welch; A W Hutcheon; I D Miller; S Payne; F Chilcott; S Waikar; T Whitaker; A K Ah-See; O Eremin; S D Heys; F J Gilbert; P F Sharp
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

7.  FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma.

Authors:  Eva Brun; Elisabeth Kjellén; Jan Tennvall; Tomas Ohlsson; Anders Sandell; Roland Perfekt; Roland Perfekt; Johan Wennerberg; Sven Erik Strand
Journal:  Head Neck       Date:  2002-02       Impact factor: 3.147

8.  Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?

Authors:  T Jansson; J E Westlin; H Ahlström; A Lilja; B Långström; J Bergh
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

9.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.

Authors:  Ronald Boellaard; Nanda C Krak; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

10.  Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET.

Authors:  E C S C Etchebehere; H A Macapinlac; M Gonen; K Humm; H W D Yeung; T Akhurst; H I Scher; S M Larson
Journal:  Q J Nucl Med       Date:  2002-06
View more
  94 in total

1.  Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET.

Authors:  Lieselot Brepoels; Marijke De Saint-Hubert; Sigrid Stroobants; Gregor Verhoef; Jan Balzarini; Luc Mortelmans; Felix M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-12       Impact factor: 9.236

2.  Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT.

Authors:  R K Doot; J S Scheuermann; P E Christian; J S Karp; P E Kinahan
Journal:  Med Phys       Date:  2010-11       Impact factor: 4.071

3.  Feasibility of (18)F-Fluorodeoxyglucose radiotracer dose reduction in simultaneous carotid PET/MR imaging.

Authors:  Mootaz Eldib; Jason Bini; Olivier Lairez; David D Faul; Niels Oesingmann; Zahi A Fayad; Venkatesh Mani
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-06-15

Review 4.  How should we analyse FDG PET studies for monitoring tumour response?

Authors:  Adriaan A Lammertsma; Corneline J Hoekstra; Giuseppe Giaccone; Otto S Hoekstra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

5.  Issues in quantification of cardiac PET studies.

Authors:  Hugo W A M de Jong; Mark Lubberink
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03       Impact factor: 9.236

6.  Predicting response to chemoradiotherapy in rectal and oesophageal cancer with 18F-FDG: prognostic value and possible role in patient management.

Authors:  Elif Hindié; Christophe Hennequin; Jean-luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

7.  Ferret thoracic anatomy by 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (18F-FDG PET/CT) imaging.

Authors:  Albert Wu; Huaiyu Zheng; Jennifer Kraenzle; Ashley Biller; Carol D Vanover; Mary Proctor; Leslie Sherwood; Marlene Steffen; Chin Ng; Daniel J Mollura; Colleen B Jonsson
Journal:  ILAR J       Date:  2012

8.  A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment.

Authors:  Robert L Harrison; Brian F Elston; Robert K Doot; Thomas K Lewellen; David A Mankoff; Paul E Kinahan
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

9.  Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.

Authors:  Hua-Xiang Xu; Tao Chen; Wen-Quan Wang; Chun-Tao Wu; Chen Liu; Jiang Long; Jin Xu; Ying-Jian Zhang; Run-Hao Chen; Liang Liu; Xian-Jun Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-13       Impact factor: 9.236

10.  PET/CT Assessment of Response to Therapy: Tumor Change Measurement, Truth Data, and Error.

Authors:  Paul E Kinahan; Robert K Doot; Michelle Wanner-Roybal; Luc M Bidaut; Samuel G Armato; Charles R Meyer; Geoffrey McLennan
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.